202 related articles for article (PubMed ID: 23400010)
21. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
Clin Ther; 2010 Jul; 32(7):1252-69. PubMed ID: 20678674
[TBL] [Abstract][Full Text] [Related]
22. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy.
Krum H; Skiba M; Gilbert RE
Diabet Med; 2003 Sep; 20(9):708-12. PubMed ID: 12925048
[TBL] [Abstract][Full Text] [Related]
23. Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.
Chekka LMS; Chapman AB; Gums JG; Cooper-DeHoff RM; Johnson JA
Am J Med; 2021 Jul; 134(7):918-925.e2. PubMed ID: 33434556
[TBL] [Abstract][Full Text] [Related]
24. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.
Calhoun DA; Lacourcière Y; Crikelair N; Jia Y; Glazer RD
Curr Med Res Opin; 2013 Aug; 29(8):901-10. PubMed ID: 23721363
[TBL] [Abstract][Full Text] [Related]
25. Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
Ferdinand KC; Pool J; Weitzman R; Purkayastha D; Townsend R
J Clin Hypertens (Greenwich); 2011 May; 13(5):366-75. PubMed ID: 21545398
[TBL] [Abstract][Full Text] [Related]
26. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.
Racine N; Hamet P; Sampalis JS; Longo N; Bastien N
J Hum Hypertens; 2010 Nov; 24(11):739-48. PubMed ID: 20147971
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy.
Suh SY; Ahn T; Bae JH; Lim DS; Lee SU; Kim YK; Hyon MS; Kim WH; Han KR; Park HK
Clin Ther; 2014 Oct; 36(10):1402-11. PubMed ID: 25146365
[TBL] [Abstract][Full Text] [Related]
28. Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study.
Toh R; Ishida T; Nishimura K; Nonaka H; Inoue Y; Kitagawa Y; Suematsu M; Miki T; Emoto N; Hirata K
Hypertens Res; 2012 Nov; 35(11):1080-6. PubMed ID: 22786569
[TBL] [Abstract][Full Text] [Related]
29. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects.
Maitland-van der Zee AH; Turner ST; Schwartz GL; Chapman AB; Klungel OH; Boerwinkle E
Am J Hypertens; 2005 Aug; 18(8):1077-83. PubMed ID: 16109321
[TBL] [Abstract][Full Text] [Related]
30. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension.
Matthews KA; Brenner MJ; Brenner AC
Clin Ther; 2013 Sep; 35(9):1423-30. PubMed ID: 23993697
[TBL] [Abstract][Full Text] [Related]
32. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
33. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
Benz JR; Black HR; Graff A; Reed A; Fitzsimmons S; Shi Y
J Hum Hypertens; 1998 Dec; 12(12):861-6. PubMed ID: 9883710
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.
Oparil S; Barr E; Elkins M; Liss C; Vrecenak A; Edelman J
Clin Ther; 1996; 18(4):608-25. PubMed ID: 8879890
[TBL] [Abstract][Full Text] [Related]
35. Comparison of nifedipine GITS and hydrochlorothiazide in the management of elderly patients with stage I-III diastolic hypertension.
Dey HM; Soufer R; Hoffer P; Wackers FJ; Black HR
Am J Hypertens; 1996 Jun; 9(6):598-606. PubMed ID: 8783785
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.
Abe M; Okada K; Matsumoto K
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1285-303. PubMed ID: 19761411
[TBL] [Abstract][Full Text] [Related]
37. Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide.
Chrysant SG; Stimpel M
J Cardiovasc Pharmacol; 1998 Mar; 31(3):384-90. PubMed ID: 9514183
[TBL] [Abstract][Full Text] [Related]
38. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
Singh S; McDonough CW; Gong Y; Bailey KR; Boerwinkle E; Chapman AB; Gums JG; Turner ST; Cooper-DeHoff RM; Johnson JA
Sci Rep; 2019 Nov; 9(1):17323. PubMed ID: 31754133
[TBL] [Abstract][Full Text] [Related]
39. [Combination antihypertensive therapy in patients with an increased risk profile].
Bartens W; Nauck M; Wanner C
Med Klin (Munich); 1996 Oct; 91(10):626-31. PubMed ID: 9019639
[TBL] [Abstract][Full Text] [Related]
40. Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Keating GM
Drugs; 2009 Jun; 69(9):1239-65. PubMed ID: 19537840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
